Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091362 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
NCT02091362 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 270 participants.
The verdict
NCT02091362, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
Study Summary
The main purpose of the trial is to determine the effect of a study drug known as LY2409021 on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when compared to placebo. The study has two periods. Each participant will receive LY2409021 or placebo in each period. At least 4 weeks will pass between periods. The study will last about 23 weeks for each participant. Participants may remain on stable dose metformin, as prescribed by their personal physician.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG LY2409021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091362
The ClinicalTrials.gov registry entry for NCT02091362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02091362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02091362 about?
NCT02091362 is a clinical study titled "A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus". The main purpose of the trial is to determine the effect of a study drug known as LY2409021 on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when compared to placebo. The study has two periods. Each participant will receive LY2409021 or placebo in each period. At...
What is the current status of trial NCT02091362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2014-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02091362?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), LY2409021 (DRUG).
Who is sponsoring clinical trial NCT02091362?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.